Mr. Hugh MacNaught reports

VENTRIPOINT ANNOUNCES NON-BROKERED CONVERTIBLE DEBENTURE UNITS PRIVATE PLACEMENT

Ventripoint Diagnostics Ltd. has arranged a non-brokered private placement of up to $500,000 of unsecured convertible debenture units, subject to TSX Venture Exchange acceptance. Each unit will comprise one unsecured convertible debenture principal amount of $1,000 convertible into common shares and 7,143 common share purchase warrants. Depending on market conditions, the corporation may increase the size of the offering, subject to approval of the exchange.

The debentures will be convertible into common shares of the company at the option of the holder at any time prior to maturity at a conversion price of 14 cents per common share. Each whole warrant will entitle the holder thereof to purchase one common share at a price of 18 cents.

The debentures will mature June 28, 2027, and will bear interest at 10 per cent, payable semi-annually in arrears in either cash or at the option of the corporation by issuance of common shares at a 20-day VWAP (volume-weighted average price), determined at time of payment, subject to exchange approval.

The corporation may pay cash finders' fees and issue common share purchase warrants of up to 4 per cent of the gross proceeds of the offering. Each finder warrant will be exercisable into one common share at an exercise price of 14 cents per common share for a period of 18 months.

The corporation will use the proceeds of the offering to finance operational costs related to sales and marketing, additional key personnel, and general working capital purposes.

All securities issued and issuable pursuant to the offering will be subject to a hold period of four months plus one day from the date of closing of the offering. The offering is subject to approval by the exchange.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS+ products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.